TESA / IPA 12mg/6mg

$65.00

In stock (can be backordered)

Buy 5 Get 1 FREE!
Add $150.00 more to unlock FREE SHIPPING

SSL Secured

Secure Checkout

Guaranteed Delivery

Third-Party Tested

Buy Tesa/IPA 12mg/6mg—Tesamorelin + Ipamorelin Research Blend

The Tesa/IPA blend combines Tesamorelin (12mg, the clinical-grade GHRH analog with FDA approval history as Egrifta) and Ipamorelin (6mg, the most selective GHRP available) in a single pre-combined research vial. This combination represents the most clinically-validated GHRH component paired with the most selective GHRP—providing dual-pathway GH secretagogue research capability through two independent receptor systems.

The 12mg:6mg (2:1) ratio reflects established research protocol parameters for studying synergistic GHRH/GHRP somatotropic axis stimulation. This is a clinically-informed ratio derived from published GH secretagogue research studying the interplay between GHRH receptor and ghrelin receptor pathways.

Dual Pathway Mechanism

Pathway 1: Tesamorelin (12mg) activates GHRH receptor on pituitary somatotrophs, stimulates GH synthesis and pulse amplitude. Clinical evidence base from FDA approval program.
Pathway 2: Ipamorelin (6mg) activates GHS-R1a ghrelin receptor independently, modulates GH pulse frequency. Selective profile: no cortisol or prolactin stimulation.
Combined Effect: Synergistic somatotropic axis stimulation through two independent receptor pathways—GHRH receptor and ghrelin receptor acting simultaneously.

Product Specifications

Compound Tesa/IPA Blend (Tesamorelin + Ipamorelin)
Components Tesamorelin (12mg) + Ipamorelin (6mg) - pre-combined
Tesamorelin FDA-approved GHRH analog - 44 aa, MW 5,136.7 g/mol (as Egrifta)
Ipamorelin Selective GHRP - 5 aa, GHS-R1a agonist, MW ~711 g/mol
Ratio 12:6 = 2:1 Tesamorelin:Ipamorelin - research-standard dual secretagogue ratio
Mechanism GHRH receptor (Tesamorelin) + GHS-R1a ghrelin receptor (Ipamorelin)
Form Lyophilized powder (co-lyophilized blend)
Purity >99% HPLC Verified for each component - Batch COA Available
Available Size 12mg/6mg (single vial)
Storage Lyophilized: -20°C | Reconstituted: 2-8°C, use within 28 days
Reconstitution Bacteriostatic Water (BAC Water)
Intended Use Research Use Only (RUO)

Frequently Ask Questions

What is the difference between Tesa/IPA and CJC/IPA?
Both are dual-pathway GH secretagogue blends combining a GHRH analog with Ipamorelin. The difference is in the GHRH component: CJC/IPA uses CJC-1295 No DAC (Modified GRF 1-29 - a 29-amino acid fragment with ~30 min half-life). Tesa/IPA uses Tesamorelin (full 44-amino acid GHRH analog with FDA clinical approval history). Tesamorelin has the stronger clinical evidence base; CJC-1295 No DAC has shorter half-life more suited to studying pulsatile GH dynamics.
Why is the ratio 12mg Tesamorelin to 6mg Ipamorelin?
The 2:1 ratio is a research-standard proportion for dual GHRH/GHRP secretagogue protocols. A higher proportion of GHRH component relative to GHRP component is used to establish GHRH receptor priming before ghrelin receptor activation - the research rationale is that GHRH receptor stimulation amplifies the GH response to subsequent GHRP activation through synergistic somatotroph sensitization.

Related Products

From

$30.00